✦ LIBER ✦

NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy

✍ Scribed by Fiona Rinaldi; Elisabeth George; Amanda I Adler

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Economic analysis of bevacizumab, cetuxi

✍ Lawrence, Donna; Maschio, Michael; Leahy, Kevin J.; Yunger, Simon; Easaw, Jacob 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 466 KB

NICE guidance on bevacizumab in combinat

✍ Nwamaka Umeweni; Kay Nolan; Helen Knight; Peter Clark 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 50 KB

PCN3 Cetuximab for the First-Line Treatm

✍ Ubago, R.; Castillo, M.A.; Flores, S.; Rodriguez, R.; Beltran, C. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PCN11 Bevacizumab in Combination with Ch

✍ Ubago, R.; Castillo, M.A.; Flores, S.; Beltrán, C. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

PCN71 Cost-Effectiveness Analysis of Cet

✍ V. Moreno; B. Martínez-Amores; J. Barriuso; L. Mezquita; I. Ibáñez de Cáceres; Á 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PCN118 COST EFFECTIVENESS OF CETUXIMAB I

✍ SG Eggington; D Garrell; I Griebsch; Y Samyshkin 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB